1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 6, 12/Feb/2026
  4. Article
Research Open Access
Like 0
Download

SDG 3: Hepatitis

Abstract

BACKGROUND

The World Health Organization aims to eliminate hepatitis B virus (HBV) by 2030 through reducing incidence and mortality. Accurate prevalence estimates are crucial to guide policies and monitor progress towards HBV elimination. However, HBV prevalence can be overestimated when relying solely on hepatitis B surface antigen (HBsAg) because of unconfirmed or false-positive results. Robust screening algorithms to improve diagnostic accuracy and minimise false positives are required.

AIM

We conducted a nationwide, population-based serosurvey to estimate HBV prevalence in Belgium by using HBsAg alone or combined with hepatitis B core antibody (anti-HBc) positivity as infection criterion.

METHODS

We analysed HBsAg and anti-HBc in a total of 4,955 left-over serum samples from severe acute respiratory syndrome coronavirus 2 sero-epidemiology studies in 2020. Samples were stratified per region, 10-year age band and sex. A confirmatory anti-HBc neutralisation assay was performed in discordant samples.

RESULTS

We detected HBsAg in 0.75% (37/4,955) of samples, of which 62.2% (23/37) were anti-HBc-negative and showed no specific anti-HBc signal in the neutralisation assay. None of the samples from ≤ 5-year-olds (n = 87) were double-positive. Weighted analysis estimated HBsAg seroprevalence at 0.74% (95% confidence interval (CI): 0.50–1.04). However, considering double HBsAg and anti-HBc positivity, an HBV prevalence of 0.25% (95% CI: 0.13–0.42) was retained. The HBsAg/anti-HBc prevalence in ≤ 33-year-olds was lower than in older adults (0.079% vs 0.36%; p = 0.015), consistent with Belgium’s vaccination policy.

CONCLUSION

This serosurvey reinforces the importance of confirmatory anti-HBc testing in HBsAg-positive samples, particularly in low-endemic countries. Incorporating anti-HBc testing improves the correctness of prevalence estimates.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.6.2500533
2026-02-12
2026-03-07
/content/10.2807/1560-7917.ES.2026.31.6.2500533
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/6/eurosurv-31-6-4.html?itemId=/content/10.2807/1560-7917.ES.2026.31.6.2500533&mimeType=html&fmt=ahah

References

  1. World Health Organisation (WHO). Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: WHO; 2024. Available from: https://iris.who.int/handle/10665/376461
  2. Furquim d’Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J. 2022;10(1):115-23. PMID: 34846093 
  3. Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, Lemoine M, et al. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-83.  https://doi.org/10.1016/j.jhep.2025.03.018  PMID: 40348683 
  4. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55.  https://doi.org/10.1016/S0140-6736(15)61412-X  PMID: 26231459 
  5. Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796-829.  https://doi.org/10.1016/S2468-1253(22)00124-8  PMID: 35738290 
  6. Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Caprio N, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill. 2015;20(35):30009.  https://doi.org/10.2807/1560-7917.ES.2015.20.35.30009  PMID: 26530499 
  7. Hahné SJ, Veldhuijzen IK, Wiessing L, Lim T-A, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13(1):181.  https://doi.org/10.1186/1471-2334-13-181  PMID: 23597411 
  8. Zuure F, Bil J, Visser M, Snijder M, Boyd A, Blom P, et al. Hepatitis B and C screening needs among different ethnic groups: A population-based study in Amsterdam, the Netherlands. JHEP Rep Innov Hepatol. 2019;1(2):71-80.  https://doi.org/10.1016/j.jhepr.2019.04.003  PMID: 32039354 
  9. Koopsen J, van Steenbergen JE, Richardus JH, Prins M, Op de Coul ELM, Croes EA, et al. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect. 2019;147:e147.  https://doi.org/10.1017/S0950268819000359  PMID: 30869044 
  10. European Centre for Disease Prevention and Control (ECDC). Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/en/publications-data/epidemiological-assessment-hepatitis-b-and-c-among-migrants-eueea
  11. Martyn E, Eisen S, Longley N, Harris P, Surey J, Norman J, et al. The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda. eLife. 2023;12:e81070.
  12. World Health Organisation (WHO). Guidance for country validation of viral hepatitis elimination and path to elimination: technical report. Geneva: WHO; 2023. Available from: https://iris.who.int/handle/10665/373186
  13. World Health Organisation Regional Office for Europe (WHO/Europe). Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections 2022-2030. Copenhagen: WHO/Europe; 2023. Available from: https://iris.who.int/handle/10665/369243
  14. World Health Organisation Regional Office for Europe (WHO/Europe). Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen: WHO/Europe; 2017. Available from: https://iris.who.int/handle/10665/344154
  15. Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017;2(2):123-34.  https://doi.org/10.1016/S2468-1253(16)30076-0  PMID: 28403982 
  16. Yonezawa H, Tanaka S, Tanaka M, Kobayashi R, Takahashi S. Efficient implementation of hepatitis B surface antigen confirmatory neutralization tests. J Infect Chemother. 2024;30(1):29-33.  https://doi.org/10.1016/j.jiac.2023.09.007  PMID: 37690522 
  17. Lee MY, Kang SY, Lee WI, Kim MH. Need for confirmatory neutralization tests for hepatitis B surface antigen tests in populations with intermediate prevalence. Lab Med. 2021;52(5):485-92.  https://doi.org/10.1093/labmed/lmab006  PMID: 33629106 
  18. Herzog SA, De Bie J, Abrams S, Wouters I, Ekinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. Euro Surveill. 2022;27(9):2100419.  https://doi.org/10.2807/1560-7917.ES.2022.27.9.2100419  PMID: 35241216 
  19. Huzly D, Nassal M, Vorreiter J, Falcone V, Neumann-Haefelin D, Gerlich WH, et al. Simple confirmatory assay for anti-HBc reactivity. J Clin Virol. 2011;51(4):283-4.  https://doi.org/10.1016/j.jcv.2011.05.009  PMID: 21632284 
  20. Rao JNK, Scott AJ. On Chi-squared tests for multiway contingency tables with cell proportions estimated from survey data. Ann Stat. 1984;12(1):46-60.  https://doi.org/10.1214/aos/1176346391 
  21. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2024. Available from: https://www.R-project.org
  22. Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol. 2006;44(6):2250-3.  https://doi.org/10.1128/JCM.00234-06  PMID: 16757632 
  23. Holtkamp C, Fiedler M, Dittmer U, Anastasiou OE. The course of Anti-HBc antibodies over time in immunocompromised hosts. Vaccines (Basel). 2022;10(2):137.  https://doi.org/10.3390/vaccines10020137  PMID: 35214596 
  24. Anastasiou OE, Widera M, Verheyen J, Korth J, Gerken G, Helfritz FA, et al. Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. J Clin Virol. 2017;93:46-52.  https://doi.org/10.1016/j.jcv.2017.06.001  PMID: 28622640 
  25. Rysgaard CD, Morris CS, Drees D, Bebber T, Davis SR, Kulhavy J, et al. Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol. 2012;12(1):15.  https://doi.org/10.1186/1472-6890-12-15  PMID: 23006828 
  26. Ly D, Yee HF Jr, Brezina M, Martin P, Gitnick G, Saab S. Hepatitis B surface antigenemia in chronic hemodialysis patients: effect of hepatitis B immunization. Am J Gastroenterol. 2002;97(1):138-41.  https://doi.org/10.1111/j.1572-0241.2002.05437.x  PMID: 11808938 
  27. Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev. 2004;25(2):105-20. PMID: 18458713 
  28. Statistics Belgium (STATBEL). Migration census 2021. Brussels: STATBEL. [Accessed: 1 July 2025]. Available from: https://statbel.fgov.be/en/themes/census/population/migration
  29. Ho E, Vanderlinden A, Govaerts L, De Fooz B, Van Damme P, Michielsen P, et al. Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country. J Virus Erad. 2024;10(1):100369.  https://doi.org/10.1016/j.jve.2024.100369  PMID: 38596321 
  30. Ho E, Michielsen P, Van Damme P, Ieven M, Veldhuijzen I, Vanwolleghem T. Point-of-care tests for hepatitis B are associated with a higher linkage to care and lower cost compared to venepuncture sampling during outreach screenings in an asian migrant population. Ann Glob Health. 2020;86(1):81.  https://doi.org/10.5334/aogh.2848  PMID: 32742939 
  31. De Brier N, Koc ÖM, De Buck E, Muylaert A, Nevens F, Vanbrabant M, et al. Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of universal vaccination and migration. Transfusion. 2021;61(7):2125-36.  https://doi.org/10.1111/trf.16431  PMID: 33955570 
  32. Kremer-Flach K, Zimmermann R, An der Heiden M, Dudareva S. Estimated number of people infected with hepatitis B and C virus in Germany in 2013: a baseline prevalence estimate using the workbook method. Front Public Health. 2025;13:1471256.  https://doi.org/10.3389/fpubh.2025.1471256  PMID: 40260160 
  33. Quoilin S, Hutse V, Vandenberghe H, Claeys F, Verhaegen E, De Cock L, et al. A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. Eur J Epidemiol. 2007;22(3):195-202.  https://doi.org/10.1007/s10654-007-9105-6  PMID: 17356926 
  34. Beutels M, Van Damme P, Aelvoet W, Desmyter J, Dondeyne F, Goilav C, et al. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol. 1997;13(3):275-80.  https://doi.org/10.1023/A:1007393405966  PMID: 9258525 
  35. Grammens T, Cornelissen L. Vaccinatiegraad. [Vaccination rate]. Brussels: Sciensano; 2021. Dutch.
  36. Mortgat L, Serrien B, Van Deynse H, Deblonde J, Van Beckhoven D. Epidemiologische surveillance van hepatitis B en C in België. Toestand op 31 december 2023. [Epidemiological surveillance of hepatitis B and C in Belgium. Status on 31 December 2023]. Brussels: Sciensano; 2025. Dutch. Available from: https://www.sciensano.be/sites/default/files/report_viral_hepatitis_2024_nl_final_version_corrected.pdf
  37. Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Gray R, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879-907.  https://doi.org/10.1016/S2468-1253(23)00197-8  PMID: 37517414 
  38. Bivegete S, McNaughton AL, Trickey A, Thornton Z, Scanlan B, Lim AG, et al. Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review. Euro Surveill. 2023;28(30):2200738.  https://doi.org/10.2807/1560-7917.ES.2023.28.30.2200738  PMID: 37498533 
  39. Brouard C, Saboni L, Gautier A, Chevaliez S, Rahib D, Richard JB, et al. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC Infect Dis. 2019;19(1):896.  https://doi.org/10.1186/s12879-019-4493-2  PMID: 31660879 
  40. European Centre for Disease Prevention and Control (ECDC). Prevention of hepatitis B and C in the EU/EEA, 2024. Stockholm: ECDC; 2024. https://www.ecdc.europa.eu/en/publications-data/prevention-hepatitis-b-and-c-eueea-2024
Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Arno+Furquim+d%E2%80%99Almeida&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Furquim d’Almeida Arno</a>, <a href="/search?value1=Erwin+Ho&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ho Erwin</a>, <a href="/search?value1=Christian+Sch%C3%BCttler&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Schüttler Christian</a>, <a href="/search?value1=Philippe+Beutels&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Beutels Philippe</a>, <a href="/search?value1=Niel+Hens&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hens Niel</a>, <a href="/search?value1=Sandra+Dudareva&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dudareva Sandra</a>, <a href="/search?value1=Pierre+Van+Damme&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Damme Pierre</a>, <a href="/search?value1=Heidi+Theeten&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Theeten Heidi</a>, <a href="/search?value1=Thomas+Vanwolleghem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vanwolleghem Thomas</a></span>. Combined HBsAg and anti-HBc testing is required to estimate hepatitis B virus seroprevalence in a low-endemic country: findings from a nationwide population-based serosurvey, Belgium, 2020. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(6):pii=2500533. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.6.2500533" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.6.2500533</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Jul 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 07 Oct 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.6.2500533
/content/10.2807/1560-7917.ES.2026.31.6.2500533
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error